BRIMOCHEK 0.2% price in UAE

Overview

Welcome to Dwaey, specifically on BRIMOCHEK 0.2% Eye Drops page.
This medicine contains an important and useful components, as it consists of Brimonidine Tartrate.
BRIMOCHEK 0.2% is available in the market in concentration 2mg/ml and in the form of Eye Drops.

INDOCO REMEDIES LIMITED is the producer of BRIMOCHEK 0.2% and it is imported from INDIA, The most popular alternatives of BRIMOCHEK 0.2% are listed downward .

Mode Of Action

Brimonidine is an alpha 2-adrenoceptor agonist which works to reduce aqueous humor production and increase uveoscleral flow.

Indication

Open-angle glaucoma
Ocular hypertension

Precaution

General Brimonidine ophthalmic solution should be used with caution in patients with known hypersensitivity to other alpha-adrenoceptor agonists. Although brimonidine had minimal effect on blood pressure and heart rate of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. Brimonidine has not been studied in patients with hepatic or renal impairment; caution should be exercised in treating such patients. Brimonidine should be used with caution in patients with depression, cerebral or coronary insufficiency. Lactation: It is not known whether this drug is excreted in milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Side Effects

Oral dryness
Conjunctival hyperemia
Allergic conjunctivitis
Eye pruritus
Rash
Photophobia
Headache
Fatigue
Dizziness
Dyspepsia
Blepharitis
Eye discharge

Contra indication

This eye drops are contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication.This product is also contraindicated in patients receiving monoaminase oxidase inhibitor therapy.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Interaction

Possibility of an additive or potentiating effect with CNS depressants e.g. alcohol, barbiturates, opiates, sedatives or anaesthetics. Caution when used with beta-blockers (ophthalmic and systemic), antihypertensives or cardiac glycosides. TCAs can affect the metabolism and uptake of circulating amines.